Follow Up - COVID-19 Rapid Clinical Updates: Strategies in COVID-19 Treatment

This is our 30 day follow up for the live session described below.

In this second in our COVID-19: Keeping Up with a Moving Target series, our experts will discuss the most recent updates on current therapies and their efficacy including remdesivir, steroids, and convalescent plasma, the state of hospitals and CVOID-19, plus highlight management of VTE in COVID-19 patients. Presented on March 9th, 2021.

Moderator:

Joseph Sweigart, MD, SFHM
 

Panelists:


Ebrahim Barkoudah, MD, MPH FACP SFHM
Nkemdilim Mgbojikwe, MD
Paul G. Auwaerter, MD, MBA, FIDSA

 

This activity was made possible in part by an educational grant from Gilead Sciences, Inc.

 

Target Audience

This activity is designed for hospitalists and front line clinicians working working with COVID-19 patients.

Learning Objectives

  • Evaluate current guidance for treatment of COVID-19 patients requiring hospitalization
  • Review COVID-19 hospitalization trends in the US
  • Discuss findings from randomized clinical trials for treatments in hospitalized COVID-19 patients
  • Understand recent recommendations regarding the diagnosis and prevention of VTE in hospitalized adult COVID-19 patients
Course summary
Course opens: 
03/09/2021
Course expires: 
12/31/2021
Your cost:
$0.00
Part of: 
Rapid Clinical Updates: COVID-19
Rating: 
0

Ebrahim Barkoudah, MD, MPH FACP SFHM

  • Research support payments from: National Institutes of Health/National Heart, Lung, and Blood Institute, Bristol Myers Squibb and Janssen
  • Payments made to Brigham and Women's Hospital for performing clinical endpoints sponsored by various entities
  • Advisory Board fees: from Bristol Myers Squibb, Janssen, Novartis, Pfizer, and Portola/Alexion.

Paul Auwaerter, MD, MBA, FIDSA

  • JNJ: Ownership equity
  • Scientific Consulting: Verily, EMD Serono
  • DMSB: Humanigen

Remaining faculty had no relevant financial or advisory relationships with corporate organizations related to this activity.

SHM CONFLICT OF INTEREST DISCLOSURE POLICY 

In accordance with the ACCME Standards for Commercial Support, SHM requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. SHM resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. All relevant financial relationships shall be disclosed to participants prior to the start of the activity.

Furthermore, SHM seeks to verify that all scientific research referred to, reported, or used in a continuing medical education (CME) activity conforms to the generally accepted standards of experimental design, data collection, and analysis. SHM is committed to providing its learners with high-quality CME activities that promote improvements in healthcare and not those of a commercial interest.

This activity was made possible in part by an educational grant from Gilead Sciences, Inc.

Price

Your cost:
$0.00
Please login or register to take this course.

Click the START button to enter the meeting evaluation.